ENHERTU(R) Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Heitor Ventura’s Post
More Relevant Posts
-
Read the MIT Technology Review’s in-depth story on how CAR-T therapies are now becoming a reality for solid tumors, including an overview of Calibr's switchable therapy. https://lnkd.in/dbafGjJt
Innovative new cell therapies could finally get at tough-to-target cancers
technologyreview.com
To view or add a comment, sign in
-
Wow! This is shocking but very true. Genomic testing is indeed a crucial aspect of personalized medicine and can significantly impact treatment decisions for cancer patients. As Howard McLeod stated about community oncology clinics “Many or most are not set up to quickly adapt to new models of care." Adapting to new models of care, advancements in treatment options, and staying up-to-date with the rapidly evolving field of genomics can be challenging for healthcare providers, particularly in busy clinical settings like oncology clinics. I have dedicated my career and my personal mission to educate on the role of genomic testing. I don’t see this getting simplified by any means but we have to do better from an industry standpoint and from a healthcare standpoint. Each and every patient diagnosed should have the same option’s no matter where they are treated. I am determined to bridge the gap and ensure that patients receive the most effective and personalized care possible. Continuing education, collaboration with other healthcare professionals, and staying informed about the latest developments in oncology and genomics are key strategies to navigate the complexities of the field. By sharing knowledge and expertise, we all are playing a vital role in advancing patient care and empowering others in the healthcare community. #knowledgeispower #personalizedtreatment #genomictesting #thisisforyoumom
Data presented at ASCO found that only a dozen out of 800 patients with NTRK-altered advanced solid tumors got Vitrakvi or Rozlytrek over a two-year period.
Very Few Patients Eligible for Tissue-Agnostic TRK Inhibitors Get Them, Real-World Analysis Shows
precisionmedicineonline.com
To view or add a comment, sign in
-
Synthetic Organic and Medicinal Chemist | Passionate Pharmaceutical R&D and CMC Leader | Small Molecule Design & Synthesis | Antibody-Drug Conjugates | New Chemical Modalities and Technologies
Nivolumab is now the first and only subcutaneously administered PD-1 inhibitor. This is a step forward to improving the patient experience with immune checkpoint inhibitor therapies, reducing the administration time from 30-60 min with IV infusion to 3-5 min with SQ injection. An oral option would still be highly desirable to further enhance patient convenience. Will we see an orally-bioavailable small molecule inhibitor of PD-1/PD-L1 in the near future? For those interested, click the link to find a review on small molecule inhibitors against the PD-1/PD-L1 interaction: https://lnkd.in/ga-we3B3.
The #FDA has accepted the BLA of subcutaneous #nivolumab for various solid tumors. https://lnkd.in/eaTy2gN9
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
targetedonc.com
To view or add a comment, sign in
-
Thanks to #GenentechResearchPathology #pathologist Amy Lo, MD, MS for her contributions to this article describing the activity of #pertuzumab #trastuzumab in patients with #HER2 expressing tumors. #ihc
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered Advanced Solid Tumors
ascopubs.org
To view or add a comment, sign in
-
A comprehensive review on actionable fusions in solid tumors, with a focus on challenges in detection, timing of testing and treatment
Fusion Challenges in Solid Tumors: Shaping the Landscape of Cancer Care in Precision Medicine | JCO Precision Oncology
ascopubs.org
To view or add a comment, sign in
-
Great to see our ASCO abstract and poster being discussed in the press! 📰 Some of the highlights: 1. Our data shows that most patients with advanced NTRK fusion-positive solid tumors are not getting the right therapy, suggesting that targeted therapy for rarer and/or tissue agnostic alterations may get deprioritized or overlooked 2. Due to the rarity these alterations other personalized medicine drugs, chemotherapy, and immunotherapies may be prioritized- physicians could not be familiar with how to manage those patients with NTRK alterations so they revert to what they know 3. Our poster shows that data-driven digital engagement could help physicians better discern precision treatment opportunities for their patients (DXRX Physician engagement solution) For more details read the article below and get in touch to know more! #precisionmedicine #oncology #biomarkers #ASCO24 #ASCO2024 https://lnkd.in/d-QVfgeJ
Data presented at ASCO found that only a dozen out of 800 patients with NTRK-altered advanced solid tumors got Vitrakvi or Rozlytrek over a two-year period.
Very Few Patients Eligible for Tissue-Agnostic TRK Inhibitors Get Them, Real-World Analysis Shows
precisionmedicineonline.com
To view or add a comment, sign in
-
TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors Science Advances https://lnkd.in/ghj8Nh5M
TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors
science.org
To view or add a comment, sign in
-
This review in BioDrugs highlights the synergistic potential of local therapies and CAR T cell treatment to overcome challenges posed by solid tumors and provides an overview of current research combining these two strategies. #carttherapy #SolidTumors #combinationtherapy https://lnkd.in/ggJ5Uju6
Prospects of Synergy: Local Interventions and CAR T Cell Therapy in Solid Tumors - BioDrugs
link.springer.com
To view or add a comment, sign in
-
Prelude is currently evaluating PRT3789 as a monotherapy and in combination with docetaxel in a Phase I study with SMARCA4-mutated tumors.
Prelude Therapeutics to Study PRT3789, Keytruda in SMARCA4-Mutant Cancers
precisionmedicineonline.com
To view or add a comment, sign in
-
Superior Tumor Detection for 68Ga-FAPI-46 Versus 18F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma https://lnkd.in/dzvUBk2j
Superior Tumor Detection for 68Ga-FAPI-46 Versus 18F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma
jnm.snmjournals.org
To view or add a comment, sign in
Owner OncoMed - Providing oncology strategic marketing solutions for the past 35 years
9moHonestly I get concerned when I réad meaningful. …and also DOR which is obviously a biased subset. Phase 3 I await with great interest.